Leo Pharma begins phase IIb study of oral atopic dermatitis drug

Pharmaceutical firm Leo Pharma has recruited the first patient for a clinical IIb trial to test the oral candidate in adults with moderate-to-severe atopic dermatitis.

Photo: Leo Pharma / PR

Clinical testing in a phase IIb study with a tablet treatment for moderate-to-severe atopic dermatitis in adult patients is now starting, says Leo Pharma in a press release.

The oral formulation has been chosen because some patients have found it easier to manage their diseases with tablet solutions.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs